勘误：转移性乳腺癌中的ESR1融合与治疗耐药性。
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer.
作者信息
Nagy Zsuzsanna, Jeselsohn Rinath
机构信息
Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, United States.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
出版信息
Front Oncol. 2023 Mar 6;13:1155540. doi: 10.3389/fonc.2023.1155540. eCollection 2023.
Abstract
[This corrects the article DOI: 10.3389/fonc.2022.1037531.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fonc.2022.1037531。]
相似文献
1
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer.勘误：转移性乳腺癌中的ESR1融合与治疗耐药性。
Front Oncol. 2023 Mar 6;13:1155540. doi: 10.3389/fonc.2023.1155540. eCollection 2023.
2
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.SERD/SERM 杂交 CDK4/6 抑制剂组合在内分泌治疗抵抗性乳腺癌模型中的疗效
Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.
3
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.内分泌治疗耐药乳腺癌中复发性高活性 ESR1 融合蛋白。
Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.
4
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance.复发性 ESR1-CCDC170 基因融合在乳腺癌内分泌耐药中的治疗作用。
Breast Cancer Res. 2020 Aug 8;22(1):84. doi: 10.1186/s13058-020-01325-3.
5
fusions drive endocrine therapy resistance and metastasis in breast cancer.融合基因驱动乳腺癌的内分泌治疗耐药性和转移。
Mol Cell Oncol. 2018 Oct 9;5(6):e1526005. doi: 10.1080/23723556.2018.1526005. eCollection 2018.
6
alterations and metastasis in estrogen receptor positive breast cancer.雌激素受体阳性乳腺癌的改变与转移
J Cancer Metastasis Treat. 2019;5. doi: 10.20517/2394-4722.2019.12. Epub 2019 May 4.
7
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.激素敏感型晚期乳腺癌患者内分泌治疗类型与雌激素受体 1 突变发展的相关性：一项随机和非随机试验的系统评价和荟萃分析。
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21.
8
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.激素受体阳性转移性乳腺癌中 ESR1 融合的临床意义和治疗策略：病例系列。
Oncologist. 2023 Feb 8;28(2):172-179. doi: 10.1093/oncolo/oyac248.
9
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.转录重编程区分内分泌治疗耐药转移性乳腺癌中活跃和不活跃的 ESR1 融合。
Cancer Res. 2021 Dec 15;81(24):6259-6272. doi: 10.1158/0008-5472.CAN-21-1256. Epub 2021 Oct 28.
10
Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.基因组编辑乳腺癌细胞模型中ESR1突变的突变位点及背景依赖性效应
Breast Cancer Res. 2017 May 23;19(1):60. doi: 10.1186/s13058-017-0851-4.
引用本文的文献
1
Harmonization trial on testing strategies in ER+/HER2- breast cancer patients: an Italian experience.雌激素受体阳性/人表皮生长因子受体2阴性乳腺癌患者检测策略的协调试验：意大利的经验
J Liq Biopsy. 2025 Jul 28;9:100314. doi: 10.1016/j.jlb.2025.100314. eCollection 2025 Sep.
2
Multiplex detection of ten mutations and E17K in breast cancer using digital PCR.使用数字PCR对乳腺癌中的十种突变和E17K进行多重检测。
J Liq Biopsy. 2024 Mar 30;5:100154. doi: 10.1016/j.jlb.2024.100154. eCollection 2024 Sep.
Zotero 插件